|Product Name||Levosalbutamol Sulphate|
|IUPAC Name||(R)-2-tert-butylamino-1-(4-hydroxy -3-hydroxymethylphenyl) ethanol Sulfate|
|Molecular Formula||(C13H21NO3)2 H2SO4|
|Appearance||Nature- Solid ( Crystalline powder)|
Colour- White or almost white
|Solubility||Freely soluble in water, Very slightly soluble in ethanol (95%) and dichloromethane|
|Patent Status||Out Of Patents|
|Therap.Cat||Beta2-adrenoceptor agonist; Bronchodilator.|
Levosalbutamol or Levalbuterol is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is marketed under the brand name Xopenex by Sunovion Pharmaceuticals Inc. The drug is the (R)-(−)-enantiomer of its prototype drug Salbutamol (INN) or Albuterol (USAN). It is available in some countries in generic formulations from pharmaceutical companies including Cipla, Teva, and Dey, among others.
Levosalbutamol’s bronchodilator properties give it indications in treatment of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. Like other bronchodilators, it acts by reducing inflammation in the bronchial tubes, and thus shortening or reversing an acute “attack” of shortness of breath or difficulty breathing. Unlike some slower-acting bronchodilators, it is not indicated as a preventative of chronic bronchial inflammation.